Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study

详细信息    查看全文

• 作者：Xuan Su ; PhD^a ; ¹ ; Caiyun He ; PhD^b ; ¹ ; Tao Tang ; MD^b ; Weichao Chen ; MD^a ; Zhaoqu Li ; MD^a ; Yong Chen ; MD^c ; Ankui Yang ; MD^a ; ^{yangak@sysucc.org.cn} ; ^{ankuiyang@sina.com}
• 刊名：American Journal of Otolaryngology
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：38
• 期：1
• 页码：52-56
• 全文大小：214 K
• 卷排序：38

文摘

The value of additional use of cetuximab with the classical cisplatin, docetaxel and 5-fluorouracil regimen in larynx preservation remains unknown. This study was designed to resolve this issue and appraise its toxicity.Materials and methodsThirteen untreated patients with stage III–IV larynx or hypopharynx squamous cell carcinoma were recruited and received two cycles of C + TPF regimen (cetuximab plus docetaxel, cisplatinand and 5-fluorouracil), followed by one more cycle of C + TPF and intensity-modulated radiotherapy (70 Gy). Primary endpoint was larynx preservation (LP) rate at 3 months. Secondary endpoints were larynx function preservation (LFP) and overall survival (OS) at 12, 36 and 60 months.ResultsWith a two-cycle induction treatment of C + TPF protocol, four (31%) and nine (69%) patients achieved complete and partial response, respectively. The top three toxicities were dermatitis (9 cases), nausea/vomiting (6 cases), and anemia (4 cases). After the full-course treatment, 12 out of 13 patients (92.3%) obtained LP at 3 months. This strategy demonstrated relatively high LFP rates of 92.3%, 69.2% and 54.5% and satisfactory OS rates of 100%, 84.6% and 54.5% at 12, 36 and 60 months, respectively.ConclusionsThese preliminary results suggest induction treatment with C + TPF regimens, followed by intensity-modulated radiotherapy is well-tolerated, which warrants further evaluation.